Wednesday, October 14, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 23, 2026

Harju Elekter Group financial results, 1-6/2026

View original at globenewswire.com
“EUR'000 ... EBITDA 2,266 4,658 -51.4% 3,905 8,523 -54.2% ... [Table header states: EUR'000]”
Verbatim excerpt from the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • In Sweden, a significant portion of the order book consists of long-term projects, with execution extending through 2028.

    60% confidence

  • Developments in the Nordic and Finnish markets provide a basis for expecting a gradual improvement in market conditions.

    60% confidence

  • Ongoing preparations combined with a growing order book create favourable conditions for servicing larger project volumes and supporting revenue growth and improved profitability in the coming years.

    60% confidence

  • The order book for the second half of 2026 is stronger compared to the first half.

    60% confidence

Data points we hold from this source

Harju Elekter Group · share capital11706 USD
Harju Elekter Group · total liabilities67612 USD
Harju Elekter Group · prepayments2330 USD
Harju Elekter Group · selling expenses1.9 USD
Harju Elekter Group · stock price5.40 EUR
Harju Elekter Group · total equity95155 USD
Harju Elekter Group · labour costs21.4 USD
Harju Elekter Group · revenue sweden14.1 USD
Harju Elekter Group · selling expense ratio4.8 percent
Harju Elekter Group · share premium3619 USD
Harju Elekter Group · reserves22729 USD
Harju Elekter Group · total current assets62845 USD
Harju Elekter Group · total current liabilities52332 USD
Harju Elekter Group · labour cost ratio27.7 percent
Harju Elekter Group · gross profit5128 USD
Harju Elekter Group · other noncurrent liabilities20 USD
Harju Elekter Group · operating expenses41.5 USD
Harju Elekter Group · operating margin2.6 percent
Harju Elekter Group · inventories20456 USD
Harju Elekter Group · retained earnings57101 USD
Harju Elekter Group · eps0.01 EUR
Harju Elekter Group · investment properties27488 USD
Harju Elekter Group · total assets162767 USD
Harju Elekter Group · revenue estonia10.1 USD
Harju Elekter Group · revenue finland17.9 USD
Harju Elekter Group · capex total3.9 USD
Harju Elekter Group · borrowings current20207 USD
Harju Elekter Group · administrative expense ratio7.3 percent
Harju Elekter Group · cash2911 USD
Harju Elekter Group · borrowings noncurrent15260 USD
Harju Elekter Group · ebitda3905 USD
Harju Elekter Group · gross margin12.2 percent
Harju Elekter Group · intangible assets10381 USD
Harju Elekter Group · noncurrent financial investments27223 USD
Harju Elekter Group · noncurrent receivables2 USD
Harju Elekter Group · current provisions283 USD
Harju Elekter Group · administrative expenses2.6 USD
Harju Elekter Group · ebit1111 USD
Harju Elekter Group · prepayments from customers6422 USD
Harju Elekter Group · property plant equipment34696 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Harju Elekter Group financial results, 1-6/2026 — Source | Via News | Via News